ENDRA Life Sciences Inc. — Director's Dealing 2017

May 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-12

Reporting Person: Thornton Michael Milos (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-12	Common Stock	C	55020	$1.40	Acquired	59987	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-12	Convertible Promissory Note	$1.40	C		Disposed	2017-05-12	Common Stock ()	Direct
2017-05-12	Stock Options	$5.00	A	313338	Acquired	2022-05-12	Common Stock (313338)	Direct

Footnotes

F1: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2).

F2: The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a
conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.

F3: These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.